期刊文献+

多药效团组合筛选PD E4B抑制剂研究 被引量:3

Combinatorial Screening of PDE4B Inhibitors based on Multiple Pharmacophores
在线阅读 下载PDF
导出
摘要 本文以17个PDE4B受体-抑制剂复合物为研究对象,应用LigandScout构建17个药效团模型,并以多药效团组合筛选方法开展中药中具有PDE4B亚型选择性抑制活性成分的辨识研究。经过配体再匹配和已知活性化合物数据库筛选两种评价方法,评价并保留了17个药效团模型;以分子被命中频次作为多药效团组合筛选方法的综合性评价指标,结合MDDR数据库筛选结果,确定了PDE4B抑制剂被命中大于或等于8次的分子为多药效团组合筛选目标。比较了最优药效团筛选方法与多药效团组合筛选方法的筛选效率,结果多药效团组合筛选方法的富集度和活性化合物有效命中率都比最优药效团筛选方法高,分别为38.017、47.44%,表明基于受体的多药效团组合筛选方法具有一定的可靠性,有助于开展中药中有效成分的辨识研究。 Seventeen receptor-based pharmacophore models of phosphodiesterase 4B (PDE4B) inhibitors were gen- erated by LigandScout based on seventeen PDE4B receptor-inhibitor complexes. The potential PDE4B selective inhibitors were identified from traditional Chinese medicine (TCM) with the method of combinatorial screening with seventeen models. By re-fitting with the ligand and screening MDL Drug Data Report (MDDR, Version 2007.2), seventeen pharmacopbores were evaluated. Based on the screening results of MDDR, hit frequency of molecules was defined as the comprehensive appraisal index of combinatorial screening. And the molecules hit by not less than eight pharmacophores were taken as the screening objects of PDE4B inhibitor. The screening efficiency by the best pharmacophore and combination of multiple pharmacophores was compared, The result showed that the enrichment and percentage of actives in the hit list of combinatorial screening were better than the best pharmacophore screening, which was 38.017 and 47.44%, respectively. The results showed that combinatorial screening method of receptor-based multiple pharmacophores is reliable and contribute to identify the active compounds from TCM. Traditional Chinese Medicine Database (TCMD, Version 2005) was screened with combinatorial screening method of multiple pharmacophores and the results would give guidance for further study of PDE4B inhibitors.
出处 《世界科学技术-中医药现代化》 北大核心 2012年第5期1996-2004,共9页 Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology
基金 科学技术部国家科技支撑计划(2008BAI51B01):中药有效成分群辨识技术研究 负责人:张宏桂 国家自然基金项目(81173522):点线面三维模拟活血化瘀中药防治冠心病的作用机制研究 负责人:张燕玲 教育部博士点基金项目(20092213120006):基于花生四烯酸代谢途径的清热解毒中药有效成分信息辨识研究 负责人:张燕玲 北京中医药大学自主课题(2011-CXTD-11):中药信息工程 负责人:乔延江 北京中医药大学自主课题(2011-JDJS-12):活血化瘀中药治疗冠心病的作用机制研究 负责人:张燕玲
关键词 磷酸二酯酶4B 基于受体药效团 多药效团组合筛选 综合性评价指标 Phosphodiesterase 4B, receptor-based pharmacophore, combinatorial screening of multiple pharmacophores,comprehensive appraisal index
  • 相关文献

参考文献25

  • 1王晓英,吴俊芳,张均田.选择性磷酸二酯酶抑制剂研究进展[J].中国药理学通报,2000,16(2):121-124. 被引量:18
  • 2Lagente V, Martin-Chouly C, Boichot E, et al. Selective PDFA in- hibitors as potent anti-inflammatory drugs for the treatment of airway diseases. Mere lnst Oswaldo Cruz, Rio de Janeiro, 2005, 100:131-136.
  • 3Robichaud A, Stamatiou PB, Jin C, et ol. Deletion of phosphodi- esterase 4D in mice shortens alpha2-adrenoceptor-mediated anes- thesia, a behavioural correlate of emesis. J Clin lnves, 2002, 110: 1045-1052.
  • 4Muftuoglu Y, Mustata G. Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett, 2010, 20:3050-3064.
  • 5Govek SP, Oshiro G, Anzola JV, et al. Water-soluble PDEd in- hibitors for the treatment of dry eye. Bioorg Med Chem Lett, 2010, 20:2928-2932.
  • 6Woodrow MD, Ballantine SP, Barker MD, et ol. Quinolines as a novel structural class of potent and selective PDE4 inhibitors: Opti- misation for inhaled administration. Bioorg Med Chem Lett, 2009, 19:5261-5265.
  • 7Lunniss C J, Cooper AW, Eldred CD, et al. Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimization for oral administration. Bioorg Med Chem Lett, 2009, 19:1380-1385.
  • 8Hambin JN, Angell TD, Ballantine SP, et al. Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors. Bioorg Med Chem Leu, 2008, 18:4237-4241.
  • 9Kranz M, Wall M, Evans B, et d. Identification of PDE4B Over 4D subtype-selective inhibitors revealing an unprecedented binding mode. Bioorg Med Chem, 2009, 17:5336-5341.
  • 10Burgin AB, Magnusson OT, Singh J, et al. Design of phosphodi- esterase 4D (PDFAD) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol, 2010, 28:63-70.

二级参考文献43

  • 1[1]Beavo JA.Cyclic nucleotide phosphodiesterases:functional implications of multiple isoforms.Physiol Rev,1995,75 (4):725-748.
  • 2[2]Conti M,Richter W,Mehats C,et al.Cyclic AMP-specific PDF4 phosphodiesterases as critical components of cyclic AMP signaling.J Biol Chem,2003,278(8):5493-5496.
  • 3[3]Castro A,Jerez M J,Gil C,et al.Cyclic nucleolide phosphodiesterases and their role in immunomodulatory responses:advances in the development of specific phosphodiesterase inhibitors.Med Res Rev,2005,25(2):229-244.
  • 4[6]Gund P.Evolution of the pharmacophore concept in pharmaceutical research/Guner OE Pharmacophore perception,development,and use in drug design.La Jolla:International University Line,2000:8-9.
  • 5[7]Kaminski JJ,Rane DF,Rothofsky ML.Database mining using pharmacophore models//Guner OF.Pharmacophore perception,development,and use in drug design.La Jolla:International University Line,2000:259-260.
  • 6[8]Funk OF,Kettmann V,Drimal J,et al.Chemical function based pharmacopliore generation of endothelin-A selective receptor antagonists.J Med Chem,2004,47(11):2750-2760.
  • 7[9]Dayam R,Sanchez T,Clement O,et al.Beta-diketo acid pharmacophore hypothesis.1.Discovery of a novel class of HIV-1 integrase inkibitors.J Med Chem,2005,48(1):111-120.
  • 8[11]Rollinger JM,Haupt S,Stupner H,et al.Combining ethnopharmacology and virtual screening for lead structure discovery:COX-inhibitors as application example.J Chem Inf Comput Sci,2004,44(2):480-488.
  • 9[12]Doddareddy MR,Choo H,Cho YS,et al.3D pharmcophora based virtual screening of T-type calcium channel blockers.Bioorg Meal Chem,2006,15(2):1091-1105.
  • 10[13]Tremelin A,Guichard E.2D-and 3D-QSAR model of interaction between flavor compounds and beta-lactoglobulin using catalyst and cerius2.QSAR Comb Sci,2004,23(4):214-233.

共引文献21

同被引文献59

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部